Segall Bryant & Hamill LLC Trims Stock Holdings in HealthEquity, Inc. $HQY

Segall Bryant & Hamill LLC lowered its stake in HealthEquity, Inc. (NASDAQ:HQY) by 4.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 169,049 shares of the company’s stock after selling 8,759 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in HealthEquity were worth $14,127,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of HQY. Capricorn Fund Managers Ltd acquired a new position in HealthEquity during the fourth quarter worth $6,926,000. Oxbow Advisors LLC purchased a new position in shares of HealthEquity during the first quarter worth $3,147,000. Westfield Capital Management Co. LP grew its stake in shares of HealthEquity by 13.7% in the fourth quarter. Westfield Capital Management Co. LP now owns 1,952,452 shares of the company’s stock valued at $178,864,000 after buying an additional 235,794 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd acquired a new stake in shares of HealthEquity in the fourth quarter valued at $4,381,000. Finally, Future Fund LLC raised its holdings in shares of HealthEquity by 40.9% in the 4th quarter. Future Fund LLC now owns 44,317 shares of the company’s stock valued at $4,060,000 after buying an additional 12,854 shares during the period. Hedge funds and other institutional investors own 99.55% of the company’s stock.

HealthEquity Stock Down 0.4%

HealthEquity stock opened at $100.61 on Friday. The firm has a market capitalization of $8.41 billion, a P/E ratio of 37.68, a P/E/G ratio of 1.69 and a beta of 0.21. The company has a current ratio of 3.44, a quick ratio of 3.44 and a debt-to-equity ratio of 0.46. HealthEquity, Inc. has a twelve month low of $72.76 and a twelve month high of $105.96. The stock’s fifty day simple moving average is $91.74 and its 200-day simple moving average is $85.12.

HealthEquity (NASDAQ:HQY) last released its earnings results on Thursday, May 28th. The company reported $1.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.11 by $0.13. HealthEquity had a return on equity of 14.75% and a net margin of 17.25%.The firm had revenue of $354.64 million during the quarter, compared to analyst estimates of $352.02 million. HealthEquity’s revenue for the quarter was up 7.2% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. As a group, equities analysts expect that HealthEquity, Inc. will post 3.92 earnings per share for the current fiscal year.

Insider Buying and Selling at HealthEquity

In other news, EVP Delano Ladd sold 7,500 shares of HealthEquity stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $90.00, for a total value of $675,000.00. Following the completion of the transaction, the executive vice president owned 91,141 shares in the company, valued at approximately $8,202,690. This trade represents a 7.60% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gayle Furgurson Wellborn sold 2,439 shares of HealthEquity stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $90.00, for a total value of $219,510.00. Following the completion of the transaction, the director owned 19,733 shares of the company’s stock, valued at $1,775,970. The trade was a 11.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 17,905 shares of company stock valued at $1,651,280 in the last quarter. Corporate insiders own 1.60% of the company’s stock.

Analyst Upgrades and Downgrades

HQY has been the topic of several research reports. Wells Fargo & Company set a $111.00 target price on HealthEquity in a research note on Monday, June 1st. Citizens Jmp lifted their target price on HealthEquity from $110.00 to $111.00 and gave the company a “market outperform” rating in a research report on Monday, June 1st. Royal Bank Of Canada boosted their price target on shares of HealthEquity from $100.00 to $108.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 3rd. KeyCorp reissued an “overweight” rating on shares of HealthEquity in a research report on Tuesday, May 26th. Finally, Weiss Ratings raised shares of HealthEquity from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, June 5th. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $110.93.

About HealthEquity

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.